Publicaciones en las que colabora con FRANCISCO VANACLOCHA SEBASTIÁN (150)

2019

  1. Erythema migrans… again

    Piel, Vol. 34, Núm. 2, pp. 123-125

  2. Genetic variation at the glycosaminoglycan metabolism pathway contributes to the risk of psoriatic arthritis but not psoriasis

    Annals of the Rheumatic Diseases, Vol. 78, Núm. 3, pp. 355-364

2017

  1. A Case Series of Patients With Psoriasis Exposed to Biologic Therapy During Pregnancy: The BIOBADADERM Register and a Review of the Literature

    Actas Dermo-Sifiliograficas, Vol. 108, Núm. 2, pp. 168-170

  2. Comparison of phenotype, comorbidities, therapy and adverse events between psoriatic patients with and without psoriatic arthritis. Biobadaderm registry

    Journal of the European Academy of Dermatology and Venereology, Vol. 31, Núm. 6, pp. 1021-1028

  3. Infections in Moderate to Severe Psoriasis Patients Treated with Biological Drugs Compared to Classic Systemic Drugs: Findings from the BIOBADADERM Registry

    Journal of Investigative Dermatology, Vol. 137, Núm. 2, pp. 313-321

  4. Management of Biologic Therapy in Moderate to Severe Psoriasis in Surgical Patients: Data From the Spanish Biobadaderm Registry

    Actas Dermo-Sifiliograficas, Vol. 108, Núm. 1, pp. 52-58

  5. Management of Biologic Therapy in Moderate to Severe Psoriasis in Surgical Patients: Data From the Spanish Biobadaderm Registry

    Actas dermo-sifiliograficas, Vol. 108, Núm. 1, pp. 52-58

  6. Possible paradoxical occurrence of inflammatory arthritis in patients with psoriasis treated with biologics: findings in the Biobadaderm cohort

    British Journal of Dermatology

  7. Secukinumab demonstrates greater sustained improvements in daily activities and personal relationships than ustekinumab in patients with moderate-to-severe plaque psoriasis: 52-week results from the CLEAR study

    Journal of the European Academy of Dermatology and Venereology, Vol. 31, Núm. 10, pp. 1693-1699

  8. Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to-severe plaque psoriasis up to 1 year: Results from the CLEAR study

    Journal of the American Academy of Dermatology, Vol. 76, Núm. 1, pp. 60-69.e9

  9. Should tumour necrosis factor antagonist safety information be applied from patients with rheumatoid arthritis to psoriasis? Rates of serious adverse events in the prospective rheumatoid arthritis BIOBADASER and psoriasis BIOBADADERM cohorts

    British Journal of Dermatology, Vol. 176, Núm. 3, pp. 643-649

2016

  1. Aphthous vulvar ulcers: A paradoxal adverse effect at distance of topical imiquimod?

    European Journal of Obstetrics and Gynecology and Reproductive Biology

  2. Development of clinical prediction models for good or bad response to classic systemic drugs, anti-TNFs, and ustekinumab in psoriasis, based on the BIOBADADERM cohort

    Journal of Dermatological Treatment, Vol. 27, Núm. 3, pp. 203-209

  3. Failure of photodynamic therapy (PDT) in 3 patients with folliculitis decalvans

    Journal of the American Academy of Dermatology

  4. Genome-Wide Pathway Analysis Identifies Genetic Pathways Associated with Psoriasis

    Journal of Investigative Dermatology, Vol. 136, Núm. 3, pp. 593-602

  5. Initial Assessment of Patients With Contact Eczema

    Actas Dermo-Sifiliograficas, Vol. 107, Núm. 9, pp. 791-793

  6. Lesiones eccematosas y cuadro ictiosiforme adquirido como forma de presentación de un linfoma anaplásico de células grandes CD30+

    Semergen: revista española de medicina de familia, Núm. 3, pp. 208-210

  7. Nagelbefall kann bei Patienten mit Psoriasis auf eine Enthesiopathie hinweisen

    JDDG - Journal of the German Society of Dermatology, Vol. 14, Núm. 11, pp. 1102-1108

  8. Survival of classic and biological systemic drugs in psoriasis: results of the BIOBADADERM registry and critical analysis

    Journal of the European Academy of Dermatology and Venereology, Vol. 30, Núm. 11, pp. 1942-1950

  9. Urine metabolome profiling of immune-mediated inflammatory diseases

    BMC Medicine, Vol. 14, Núm. 1